Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
Gallien
Sébastien
S
Assistance Publique Hôpitaux de Paris, Hôpital Saint-Louis, Department of Infectious Diseases, University of Paris-Diderot/Paris 7, Paris, France. sebastien.gallien@sls.aphp.fr
Journot
Valérie
V
Rozenbaum
Willy
W
Yéni
Patrick
P
Morlat
Philippe
P
Poizot-Martin
Isabelle
I
Reynes
Jacques
J
Reliquet
Véronique
V
Leclercq
Pascale
P
Simon
François
F
Chêne
Geneviève
G
Molina
Jean-Michel
JM
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D048588:Benzoxazines / Q000008:administration & dosage*; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016049:Didanosine / Q000008:administration & dosage*; D000068679:Emtricitabine; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D012367:RNA, Viral; D003841:Deoxycytidine; D000068679:Emtricitabine; C098320:efavirenz; D016049:Didanosine